Switch to agalsidase alfa after shortage of agalsidase beta in Fabry disease: a systematic review and meta-analysis of the literature.
Antonio PisaniDario BruzzeseMassimo SabbatiniLetizia SpinelliMassimo ImbriacoEleonora RiccioPublished in: Genetics in medicine : official journal of the American College of Medical Genetics (2016)
The nine studies (217 patients) included in our systematic review showed only marginal differences in most of the evaluated parameters. Seven of these studies were included in the meta-analysis (176 patients). The pooled incidence rate of major adverse events was reported for five studies (150 patients) and was equal to 0.04 events per person-year. No significant change was observed after the shift in glomerular filtration rate, whereas left ventricular mass index, left ventricular posterior wall dimension, and ejection fraction were significantly reduced over time. Our data showed that the switch to agalsidase alfa was well tolerated and associated with stable clinical conditions.Genet Med 19 3, 275-282.
Keyphrases
- ejection fraction
- systematic review
- aortic stenosis
- left ventricular
- end stage renal disease
- newly diagnosed
- meta analyses
- prognostic factors
- acute myocardial infarction
- machine learning
- clinical trial
- mitral valve
- deep learning
- artificial intelligence
- big data
- atrial fibrillation
- patient reported
- transcatheter aortic valve replacement
- percutaneous coronary intervention
- double blind